Shengxiang Biotech (688289.SH) announced that the company expects to become a parent company in the first quarter of 2024...
Zhitong Finance App News, Shengxiang Biotech (688289.SH) announced that the company expects to achieve net profit of 81.4891 million yuan in the first quarter of 2024, which is an increase of 21.4762 million yuan compared with the same period last year, an increase of 21.4762 million yuan, an increase of 35.79% over the previous year.
In the context of the country making every effort to promote the high-quality development of the life and health industry, the company has gradually entered a period of strength in multiple tracks and fields with early forward-looking strategic planning and investment layout. Endogenous drive and epitaxial growth go hand in hand, showing strong growth potential. At the same time, the company actively captures and utilizes market opportunities, promotes the breadth and depth of product coverage, provides more solutions for hospitals, disease control, communities, the Internet, etc., further enhances product performance, optimizes customer experience, effectively achieves collaborative business growth, continuously enhances the company's brand influence, and lays a solid foundation for future sustainable development.